Benjamin E Stein1, David Alex Stroh, Lew C Schon. 1. Department of Orthopaedic Surgery, MedStar Union Memorial Hospital, 3333 North Calvert Street, Suite 400, Baltimore, MD, 21218, USA.
Abstract
PURPOSE: Optimal treatment of acute Achilles tendon ruptures remains controversial. Positive results using stem-cell-bearing concentrates have been reported with other soft-tissue repairs, but no studies exist on outcomes of bone marrow aspirate concentrate (BMAC) augmentation in primary Achilles tendon repair. METHODS: We reviewed patients with sport-related Achilles tendon ruptures treated via open repair augmented with BMAC injection from 2009 to 2011. Data on operative complications, strength, range of motion, rerupture, calf circumference and functional improvement through progressive return to sport and the Achilles tendon Total Rupture Score (ATRS) were analysed. RESULTS: A total of 27 patients (28 tendons) treated with open repair and BMAC injection were identified (mean age 38.3 ± 9.6 years). At mean follow-up of 29.7 ± 6.1 months, there were no reruptures. Walking without a boot was at 1.8 ± 0.7 months, participation in light activity was at 3.4 ± 1.8 months and 92% (25 of 27) of patients returned to their sport at 5.9 ± 1.8 months. Mean ATRS at final follow-up was 91 (range 72-100) points. One case of superficial wound dehiscence healed with local wound care. No soft-tissue masses, bone formation or tumors were observed in the operative extremity. CONCLUSIONS: Excellent results, including no re-ruptures and early mobilisation, were observed in this small cohort with open Achilles tendon repair augmented by BMAC. No adverse outcomes of biologic treatment were observed with this protocol. The efficacy of BMAC in the operative repair of acute Achilles tendon ruptures warrants further study. LEVEL OF EVIDENCE: IV - Therapeutic.
PURPOSE: Optimal treatment of acute Achilles tendon ruptures remains controversial. Positive results using stem-cell-bearing concentrates have been reported with other soft-tissue repairs, but no studies exist on outcomes of bone marrow aspirate concentrate (BMAC) augmentation in primary Achilles tendon repair. METHODS: We reviewed patients with sport-related Achilles tendon ruptures treated via open repair augmented with BMAC injection from 2009 to 2011. Data on operative complications, strength, range of motion, rerupture, calf circumference and functional improvement through progressive return to sport and the Achilles tendon Total Rupture Score (ATRS) were analysed. RESULTS: A total of 27 patients (28 tendons) treated with open repair and BMAC injection were identified (mean age 38.3 ± 9.6 years). At mean follow-up of 29.7 ± 6.1 months, there were no reruptures. Walking without a boot was at 1.8 ± 0.7 months, participation in light activity was at 3.4 ± 1.8 months and 92% (25 of 27) of patients returned to their sport at 5.9 ± 1.8 months. Mean ATRS at final follow-up was 91 (range 72-100) points. One case of superficial wound dehiscence healed with local wound care. No soft-tissue masses, bone formation or tumors were observed in the operative extremity. CONCLUSIONS: Excellent results, including no re-ruptures and early mobilisation, were observed in this small cohort with open Achilles tendon repair augmented by BMAC. No adverse outcomes of biologic treatment were observed with this protocol. The efficacy of BMAC in the operative repair of acute Achilles tendon ruptures warrants further study. LEVEL OF EVIDENCE: IV - Therapeutic.
Authors: Nicklas Olsson; Karin Grävare Silbernagel; Bengt I Eriksson; Mikael Sansone; Annelie Brorsson; Katarina Nilsson-Helander; Jón Karlsson Journal: Am J Sports Med Date: 2013-09-06 Impact factor: 6.202
Authors: Thorsten Schepull; Joanna Kvist; Hanna Norrman; Marie Trinks; Gösta Berlin; Per Aspenberg Journal: Am J Sports Med Date: 2010-11-03 Impact factor: 6.202
Authors: Matthias Knobe; Gertraud Gradl; Kajetan Klos; Johannes Corsten; Thomas Dienstknecht; Bjoern Rath; Tolga Taha Sönmez; Christian Hoeckle; Hans-Christoph Pape Journal: Int Orthop Date: 2014-12-13 Impact factor: 3.075
Authors: Scott A Rodeo; Demetris Delos; Riley J Williams; Ronald S Adler; Andrew Pearle; Russell F Warren Journal: Am J Sports Med Date: 2012-04-10 Impact factor: 6.202
Authors: Lew C Schon; Nicholas Gill; Margaret Thorpe; Joel Davis; Joshua Nadaud; Jooyoung Kim; Jeremy Molligan; Zijun Zhang Journal: J Transl Med Date: 2014-05-02 Impact factor: 5.531
Authors: Mohamed A Imam; James Holton; Saman Horriat; Ahmed S Negida; Florian Grubhofer; Rohit Gupta; Ali Narvani; Martyn Snow Journal: SICOT J Date: 2017-10-09